# Current Opinion in **Pulmonary Medicine**

#### **AUTHOR INSTRUCTIONS**

Current Opinion publishes commissioned articles only. We are unable to consider unsolicited manuscripts for publication.

Manuscripts must be formatted correctly before they can be accepted for publication.

### **Redundant or duplicate publication**

Your paper should not have been published in its current form or a substantially similar form (in print or electronically, including on a web site), or accepted for publication elsewhere, and it must not be under consideration in another publication. The ICMJE has provided details of what is and what is not <u>duplicate</u> or redundant <u>publication</u>. If you are in doubt, contact the Editorial Office.

#### **Conflicts of interest**

Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as 'none'. All sources of funding and conflicts of interest should be acknowledged in the manuscript (see the below paragraph: Acknowledgements).

Refer to the submission checklist (found in Editorial Manager – My Accepted Invitations – View Proposal) before uploading your paper. Detailed guidance on format is provided below. An example manuscript is also available on the journal website.

# Aims of the journal

The *Current Opinion* journals were developed out of the recognition that specialists have increasing difficulty in keeping up to date with the expanding volume of information published in their subject.

We aim to help the reader by providing in a systematic manner:

- 1. The views of experts on current advances in the field, in a clear and readable format.
- Selections, annotated by experts, of the most interesting papers from the great wealth of original publications.
- 3. Comprehensive bibliographic listings from the major journals for the field.

Reviewers write short articles in which they present developments in their topic, emphasising the aspects that, in their opinion, are the most important. In addition, they provide short annotations to the papers published in their topic during the period reviewed (during the past 12-18 months). This selected bibliography is printed at the end of each review. Papers chosen by a reviewer as being 'of special interest' or 'of outstanding interest' are clearly identified.

#### Selection of articles for review

You should review recent articles published in your subject, with particular emphasis on those articles published during the review period (during the past 12-18 months).

#### The review

Your review should highlight and discuss all interesting developments in your subject, as reflected in the recent literature. In addition to describing recent trends, you are encouraged to give your own opinions of the topics discussed. However, be particularly careful of expressing conclusions in a way that might be construed as biased against a particular researcher, product or manufacturer.

Non-native speakers of English: Authors who are not native speakers of English and require help in writing an article in English are encouraged to consider using a language service in preparing a manuscript submission. Wolters Kluwer, in partnership with Editage, offers such services - for more information please visit <a href="http://wkauthorservices.editage.com">http://wkauthorservices.editage.com</a>. Please note that the use of this or other services are at the author's own expense and risk, and independent from the editorial processes of this journal, and does not guarantee that an article will be accepted for publication.

# **Manuscript format**

The review must be double-spaced, approximately 2,500 words in length (excluding references) and must contain the following:

**Title page:** stating the title, authors and their affiliations, and full contact details for the corresponding author (including phone number and email address).

This should also include disclosure of funding received for this work from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s).

Current Opinion papers should have a maximum of 3 authors. The journal does not consider Artificial Intelligence authoring tools to meet the requirements for Authorship as recommended by the ICMJE. The use of such tools may be included in the article's Acknowledgements.

**Structured abstract:** No longer than 200 words and must not contain references. The abstract should be structured into the following subheadings:

*Purpose of review:* describe why this review is timely and relevant.

Recent findings: describe the main themes in the literature covered by the article.

*Summary:* describe the implications of the findings for clinical practice or research.

*Keywords:* 3-5 keywords relevant to the paper should be listed.

Introduction: A paragraph outlining the scope of the review and mentioning any earlier work which will place the review in context.

**Text of review:** Include headings and titled paragraphs to subdivide the text. Ensure that at least one sentence divides each heading (i.e. do not have a subheading directly beneath a full heading).

**Conclusion:** A short paragraph drawing together the implications of the review topic and, if appropriate, giving suggestions for future research.

**Key points:** Include 3-5 key bullet points that summarise your article after the main text. Each bullet is to be no longer than one sentence.

Acknowledgements: The acknowledgements section should contain the following distinct statements in separate paragraphs:

- 1. Acknowledgements. Made only to those who have made a substantial contribution to the article. If there was no assistance state: none.
- 2. Financial support and sponsorship. You must reference all relevant sources of funding concerning this article and include grants and support which are not exclusive to the *Current Opinion* article. If there were no sources of funding, please state: none.

3. Conflicts of interest. You must reference all relevant conflicts of interest concerning this article. If there are no conflicts of interest, please state: none.

Reference section: References in numerical sequence (Vancouver style) and should include the first three authors or all authors if there are four or fewer. Important references from within the review period should be annotated and bulleted as detailed below.

Figure titles and legends: These must be provided for all figures and should be included in the main body of the text following the references.

Figures and tables: important information

All figures and tables must be cited in the text.

You are encouraged to include up to four additional elements in your review (i.e. a combination of figures and tables).

Arial or Helvetica font size 7 for any text or labels within figures.

All illustrations should be labelled as figures, and figures should be cited in the main text of the review in numerical order. The figure should have a title and a legend which describes the figure in full. All abbreviations used in the figure and not in the main text should be defined at the end of the legend.

Tables should be used to tabulate data discussed in further detail in the review, should always be referred to in the main text of the article, and should have an appropriate title.

#### Figures and tables must be:

- Original whenever possible.
- Clearly marked as "original" or "previously published" upon submission.
- Accompanied by full source details when not original. When reusing previously published figures please ensure they are the same as the original and not adapted.
- Figures and tables should not be embedded within the text but should be submitted as separate files.
- Figures should be in JPEG, TIFF, EPS, PPT or WORD formats and should have a resolution of at least 300 dpi to be suitable for printing. Please see <u>Creating Digital Artwork (PDF)</u> for the full digital artwork requirements.

If you wish to use illustrations or tables that have been *previously published,* please obtain the artwork from the authors and provide full source details. We will seek the Publisher's permission to reproduce such figures.

#### Please note:

- Abbreviations: these should be used sparsely and defined on their first appearance. Any abbreviations that are not accepted by international bodies should be avoided.
- Manufactured products, equipment and drugs: give the manufacturer, town (state) and country in brackets.
- Quotations: the source should be referenced, and the page number given in brackets in the text
- Colour figures: colour figures are produced in colour online, and in black and white in the print version, free of charge. If you would like your figures to be produced in colour in the print version, there is a \$1,000 charge.

# **Supplementary material**

We have the facility to include additional or supplementary information (e.g. tables/figures/videos/audio) with articles. This supplementary material will be published online only and will not appear in the print issue.

# **Bullets and annotations**

The important references from the period reviewed must have one or two bullets and an annotation. These are a key feature of Current Opinion journals.

#### **Bulleted references must:**

- Have been published during the review period (during the past 12-18 months). Any annotations on references older than 18 months will be removed.
- Have one bullet (\*) for special interest and two bullets (\*\*) for outstanding interest.
- Be annotated with a brief description of the paper's importance. For example:

## One bullet annotations:

\* Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66:351–357.

This is the first clinical trial to demonstrate the efficacy of B-cell depletion in SjS. This article highlights the importance of B cells in the pathogenesis of SjS.

#### Two bullet annotations:

\*\* Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007; 66:700–703. This study describes the elevation in BAFF levels that occurs in serum of patients who have been treated with B-cell depleting agents. This observation may have important consequences, following treatment, in promoting the corruption of B-cell tolerance and leading to disease relapse.

When referencing and annotating your own work from previously published material you are limited to one bullet point.

Video abstract: Authors are encouraged to create a video abstract to accompany their article. This is optional, but we highly recommend this as it will help to increase the visibility of and profile of your article. Video abstracts should be uploaded at the same time as your article as a digital file of no more than 100MB. Invited authors can find guidelines for the preparation of the video abstract, along with links to samples, can be found in Editorial Manager – My Accepted Invitations – View Proposal.

### **Submitting your paper**

Manuscripts should be submitted online through our online submission system.

- Click 'Login' and then enter your username and password and click 'Author Login'.
- Click on 'My Accepted Invitations' to begin the submission process and follow the steps onscreen.
- Figures and tables should be submitted as separate files. The manuscript file should include the text, references, structured abstract, keywords, figure legends and author address.
- We cannot publish your paper without all authors completing the copyright transfer information online. During submission, please list all co-authors when prompted. They will receive an email asking them to confirm author status and complete the required information.

#### **Open access**

Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of submission. Please note that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.

The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our Wolters Kluwer Hybrid Open Access Journals page.

### Authors retain copyright

Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.

#### **Creative Commons license**

Open access articles are freely available to read, download and share from the time of publication under the terms of the <u>Creative Commons License</u>

<u>Attribution-Non Commercial No Derivative (CC BY-NC-ND) license</u>. This license does not permit reuse for any commercial purposes, nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.

# Compliance with funder mandated open access policies

An author whose work is funded by an organization that mandates the use of the <u>Creative Commons</u>

<u>Attribution (CC BY) license</u> is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found <u>here</u>.

#### **Read and Publish Agreements**

Wolters Kluwer currently has read-and-publish agreements with institutional consortia listed here.

Corresponding authors who are affiliated with the participating institution and who qualify as eligible authors\* can publish their eligible articles open access in the eligible LWW journals at no direct cost to them. Please see your institution's individual policy for guidance on eligible article types and license choice. To qualify for the APC waiver, the corresponding author must provide their participating institution's name and institutional email address in the journal's submission system. On acceptance, the corresponding author will be asked to place an open access order in the publisher's payment portal where they will be able to request the APC be funded in accordance with this agreement. A \$0.00 APC will then be applied.

\*Eligible authors: Corresponding authors who are teaching and research staff employed by or otherwise accredited to one of the participating institutions as well as students enrolled or accredited to one of the institutions and who want to publish open access articles.

# Compliance with National Institutes of Health Accessibility Requirements

The National Institutes of Health (NIH) requires authors to submit the "post-print" (the final manuscript, in Word format, after peer-review and acceptance for publication but prior to the publisher's copyediting, design, formatting, and other services) of research the NIH funds to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the NIH to PubMed Central.

#### FAQ for open access

https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access/faq

#### **References: further information**

Articles (published or in press) should be included in the reference list at the end of the review. They should be numbered consecutively in the order in which they are cited in the text (Vancouver system). Abstracts should also be entered in the reference list with full publication details of the source.

Every study mentioned in the text must be accompanied by a relevant reference.

References cited in figures or tables must be numbered in sequence, according to the position of the first text citation of the figure or table.

Unpublished data, submitted manuscripts and personal communications must be referenced in the text only as follows:

- Personal communication: (Churchill SW, personal communication).
- Submitted paper: (Bell S, Gordon S, unpublished data).

Authors are responsible for the accuracy of the references and for obtaining permission to use personal communications.

#### **Reference format**

In the text, reference citations should be typed inside square brackets, e.g. [1]. Asterisks should be used to indicate bulleted references, e.g. [1,2,3\*,4\*\*]. In the reference list, bulleted references should include the asterisk to the left of the number, with the annotation beneath the reference details (see below).

Please list the first three authors for each reference and then *et al*, unless there are four authors or fewer, in which case all authors should be listed. Provide full reference details (*author(s)*, *title*, *journal*, *year*, *volume*, *pages*). Capitalise the first letter and all initials of authors' names, the first letter of the title of the paper, and any proper nouns in the title.

Journal names should be abbreviated as in the *Index Medicus*. If you are not familiar with the appropriate abbreviation, then the journal name should be given in full.

# References should be structured as follows: Journal:

\* Author A, Author B, Author C. Title of the paper. Journal Abbreviation 2000; 4:25–27. With annotation describing importance of reference, if bulleted.

#### Book:

\* Author A, Author B, Author C. Title of the book section. In: Book name. Edition number. Edited by Editor A, Editor B, Editor C (editors). Location of Publisher: Publisher; 2000. pp. 25–27. With annotation describing importance of reference, if bulleted.

Annotations should highlight the importance of papers published during the review period.

Annotations should not summarise the content of a paper. 75–80% of papers published during the annual period of review should be given one bullet and have a short (one or two line) annotation describing the paper's interest to the reader. Papers that are of outstanding interest and are essential reading should be given two bullets and a more comprehensive annotation.

At least 80% of the references in a review should be from the period reviewed (published in the past year to 18 months). Most of these should have one or two bullets and annotations.

Any annotations on references from outside the review period will be removed.

Preprints: Work posted on a preprint server, which identifies a preprint as not peer-reviewed, will be considered for publication. The author should declare preprint server deposition on submitting their article to the Journal. If the article is accepted, to ensure readers can find and cite the final published version, authors should add the Digital Object Identifier (DOI) of the published journal article to the posted preprint version.



@CO Pulmonary Md

FAQs including permission requests and reprints
Copyright/Disclaimer Notice • Privacy Policy